Coronavirus: Human antibody, analyzed
An international research group has analysed the active neutralizing human antibodies against the Coronavirus SARS-CoV-2, which act on the novel pathogen strongly neutralizing, and thus prevent re-infection.
Many professionals assume, that convalescent patients have only a low risk of developing cancer a second Time to COVID-19. Scientific studies have shown that people develop after previous infection-specific antibodies (the body’s own defensive substances) against the Coronavirus SARS-CoV-2. Researchers have now described the use of highly active human antibodies scientific.
Threat to global health
As the University hospital of Leipzig, in a recent communication, writes, represents the COVID-19 pandemic is a major threat to global health, and currently there are hardly any medical counter-measures. In addition, the in-depth understanding of the molecular mechanisms of the body’s own immune system is missing so far.
An international research team now managed to describe the highly active neutralizing human antibodies against the Coronavirus SARS-CoV-2 scientific. Humboldt-Professor Jens Meiler, of the University of Leipzig participated in the study, which was published recently in the journal “Nature”.
Strong neutralizing effect
Highly active neutralizing human antibodies against the Coronavirus SARS-CoV-2 can be used for the development of vaccines, as well as in the case of an acute infection for the treatment to be used.
The international research group under the direction of James E. Crowe, Vanderbilt University, Nashville, USA, had analysed human antibodies from infected patients from Wuhan, China, came.
The information suggests that these antibodies act on the Coronavirus strong neutralizing effect and thus prevent a re-infection. In various animal models, the scientists were able to demonstrate to researchers that the antibodies protect against weight loss and the inflammation of the lungs, and the viral load can decrease.
According to the experts, the present study is to provide results of a structure-based framework for a rational vaccine design and the selection of immune therapeutics.
Function the antibodies have a better understanding of
“I have assisted my American colleagues to understand the structure and function of the human anti body”, explains the Director of the Institute for drug development of the Medical faculty, Humboldt-Professor Jens Meiler, Leipzig’s share of the study.
According to the communication, the bioinformatics scientist and chemist and one of the world’s most renowned researchers in the field of computer-aided drug development. The scientists modeled with the help of digital simulations and artificial intelligence proteins, the attractive starting points for different medication. Its Institute for drug development at the Medical faculty of the University of Leipzig is currently under construction. (ad)